The alliance will give clients fully-integrated access to the expertise of Domainex in protein expression, biochemical assays, hit identification, computational and medicinal chemistry; and to Cresset’s approach to hit identification and drug design using its proprietary computational technologies.
“We are delighted to be announcing this alliance with Cresset,” said Eddy Littler, chief executive officer, Domainex. “The combination of Domainex’s drug discovery skills and the computational chemistry technologies and expertise of Cresset means that together we can offer customers an unrivalled capability to identify novel hit compounds against important drug targets, and to progress these all the way to candidate drugs. In particular Cresset’s patented field point technology and associated ligand-based approaches to targets such as GPCRs and ion-channels will perfectly complement Domainex’s own expertise in target areas such as enzymes and protein-protein interactions. We look forward to developing our relationship, and enhancing the success of our client programs through the combination of our skills and competences.”
He added, “We have recently announced that we will be moving our laboratories to a new and larger facility at Chesterford Research Park. Our alliance with Cresset provides a complementary expansion of the range of computational technologies that we can apply to client projects, and directly integrates with our well-established skills in assay development, medicinal and computational chemistry.”
Rob Scoffin, chief executive officer, Cresset, said, “We are very excited about the opportunity to partner with another world-class research services company in order to offer unrivalled capabilities in drug discovery and development. We are able to provide integrated services which will include access to Cresset’s existing applications as well as our pipeline of cutting edge computational science and yet-to-be-commercialized methods.”